---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-076553"
form_type: "8-K"
ticker: "PSNL"
cik: "0001527753"
company_name: "Personalis, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:33:50.155122+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Personalis reports 400% clinical test volume growth in 2025, guides $78-80M FY2026 revenue

## Summary
- Clinical volume surged 400% YoY to 16,233 tests; Q4 sequential growth 41% to 6,183 tests.
- Total FY2025 revenue $69.6M (down 18% YoY); clinical test revenue more than doubled to $2.0M.
- Ended 2025 with ~$240M cash, including $109M net from ATM at $8.43/share average.
- Secured Medicare coverage for breast and lung cancer surveillance; key catalyst for MRD.
- FY2026 guidance: total revenue $78-80M, clinical revenue $10-11M (5x growth), net loss ~$105M.

## SEC filing metadata
- accession: 0001193125-26-076553
- form_type: 8-K
- ticker: PSNL
- cik: 0001527753
- company_name: Personalis, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1527753/000119312526076553/0001193125-26-076553-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1527753/000119312526076553/psnl-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-076553
- JSON: https://secwatch.observer/filing/0001193125-26-076553.json
- Plain text: https://secwatch.observer/filing/0001193125-26-076553.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.